Abstract: A method and system for automatically converting forms generated using a desktop forms development tool to be compatible with mobile devices, for deploying the converted forms to the mobile devices, and for running converted forms on the mobile devices is provided. A forms system provides a conversion component, a deployment component, and a device component. A forms file is generated to be processed by a forms display program on a variety of devices. The forms system transforms the forms file to a target form file designed for execution by a target forms display program on a device of the target device type.

Abstract: A method and system for automatically converting forms generated using a desktop forms development tool to be compatible with mobile devices, for deploying the converted forms to the mobile devices, and for running converted forms on the mobile devices is provided. A forms system provides a conversion component, a deployment component, and a device component. A forms file is generated to be processed by a forms display program on a variety of devices. The forms system transforms the forms file to a target form file designed for execution by a target forms display program on a device of the target device type.

Abstract: A method and system for automatically converting forms generated using a desktop forms development tool to be compatible with mobile devices, for deploying the converted forms to the mobile devices, and for running converted forms on the mobile devices is provided. A forms system provides a conversion component, a deployment component, and a device component. A forms file is generated to be processed by a forms display program on a variety of devices. The forms system transforms the forms file to a target form file designed for execution by a target forms display program on a device of the target device type.

Abstract: This invention proposes that the best therapeutic strategy for treating and/or preventing Alzheimer's disease (AD), age related macular degeneration (AMD) and other diseases that exhibit extra-cellular debris deposits, such as atherosclerosis, is the inhibition of the complement pathway. A model for the accumulation of extra-cellular debris through the activation of the complement pathway is presented, and the primary pathogenic role of the debris in the etiology of the disorders is explained. Previously identified complement inhibitors are identified as therapeutic agents for the treatment and/or prevention of AD, AMD and other diseases that exhibit extra-cellular debris deposits.